Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Moderna Shares Plunge
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal sales" in 2024. Analysts' concerns were heightened by the company's revised sales forecast for 2024, which projects $3 billion to $3.1 billion, falling at the low end of previous estimates.
Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billion
Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year.
Moderna shares plunge after company cuts vaccine sales outlook
The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.
1d
on MSN
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.
1d
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
7h
Moderna stock drops on lower 2025 guidance, more cost cuts
Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock ...
1d
on MSN
Why Moderna Stock Just Crashed 21%
Moderna 's ( MRNA -20.49%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...
FiercePharma
1d
JPM25: Moderna slashes guidance, plots $1B in cost cuts this year amid lackluster vaccine sales
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...
14h
on MSN
Watch These Moderna Price Levels as Stock Plummets After Slashing 2025 Revenue Outlook
Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its ...
1d
on MSN
Moderna 2025 Revenue Guidance Below Wall Street’s Estimates
The biotech company said it expects between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...
20h
Moderna’s Financial Outlook Dims Amid Vaccine Challenges and Revised Sales Forecasts, Warrants Sell Rating
In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a ...
20h
Biogen, Moderna, and other Mass. biotech firms making headlines amid JPMorgan Healthcare Conference
“In the end," Vrabel said. "It was clear to me, and to my family, and my soul, that this was the place that I wanted to be.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
United States
S&P 500 Index
COVID
NASDAQ
norovirus
Feedback